Teknova and Pluristyx collaborate to streamline cell therapy manufacturing with PluriFreeze cryopreservative system

From GlobeNewswire: 2025-03-11 19:00:00

Alpha Teknova, Inc. and Pluristyx, Inc. are collaborating to produce and commercialize PluriFreeze™, a cryopreservative system for allogeneic cell therapies. PluriFreeze simplifies cell product manufacturing and will be exclusively distributed by Teknova in the US and Canada. The system is entirely synthetic and animal-origin-free, consisting of a base wash and a freezing medium. Teknova’s President, Stephen Gunstream, highlights the collaboration’s potential in streamlining cell therapy manufacturing. More details about pricing and availability will be announced at the upcoming BioProcess International West conference. Interested parties can sign up for early access on Teknova’s website.



Read more at GlobeNewswire: Teknova and Pluristyx Announce Collaboration to Streamline